Last Price$33.90.6%
Market Cap$15.2B
LTM Free Cash Flow
$2,769.5M
Reverse DCF (Implied FCF growth)
(28.7%)
3Y Free Cash Flow CAGR
(13.0%)
LTM Revenue
$2,263.9M
Reverse DCF (Implied Revenue growth)
(20.9%)
at normalized FCF margin 73.2%
3Y Revenue CAGR
(0.4%)
RPRX Reverse DCF Model
Implied FCF growth
Implied Revenue growth
Reverse DCF Assumptions and Outputs
as of Dec 31, 2024
2,769.5M
Long-Term growth rate
3.0%
5.0%
FX rate
1.0
Last share price
25.5
Implied FCF growth 1-10Y
(28.7%)
Implied Free Cash Flow growth vs Historical average vs Industry growth
Best stock ideas on the market right now
With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Low P/E stocks
Explore the best low P/E stocks to buy in 2025, featuring top companies trading at low P/E ratios.
3M Return 7.5%
S&P Outperformance -5.5%
Next 3M Predicted Return 10.2%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
RPRX Free Cash Flow
Annual
Quarterly
LTM
RPRX Growth
Annual
Quarterly
LTM
Industry Median
5Y Historical Average
Benchmark
Crunching data... Almost there!
Crunching data... Almost there!
RPRX vs Peer Set: Reverse DCF comparison
Implied FCF growth
Implied Revenue growth
General
REVERSE DCF
Financial metrics
Company name
Implied Free Cash Flow growth
FCF margin
3Y avg FCF growth
3Y avg Revenue growth
Royalty Pharma plcRPRX
(28.7%)
122.3%
4.8%
4.0%
Median Peer Set
2.8%
51.2%
36.1%
Incyte CorporationINCY
16.2%
5.5%
61.7%
25.6%
Novo Nordisk A/SNVO
10.0%
24.1%
13.5%
12.0%
BioNTech SEBNTX
2.5%
32.4%
339.3%
697.4%
Regeneron Pharmaceuticals, Inc.REGN
1.6%
25.3%
33.7%
24.3%
United Therapeutics CorporationUTHR
(3.0%)
37.6%
23.5%
10.5%
Alnylam Pharmaceuticals, Inc.ALNY
(100.0%)
(1.9%)
28.6%
46.6%
argenx SEARGX
(100.0%)
(9.4%)
42.4%
151.5%
BeiGene, Ltd.BGNE
(100.0%)
(30.4%)
220.8%
2,252.2%
Summit Therapeutics Inc.SMMT
(100.0%)
N/A
59.9%
97.2%
Vertex Pharmaceuticals IncorporatedVRTX
(100.0%)
(7.2%)
100.2%
23.9%
Explore more intrinsic value tools hub for RPRX
DCF value calculator
Peter Lynch Fair Value
Discount rate
Relative Value
Earnings growth model
Peter Lynch charts
Margin of safety
Intrinsic Value
Earnings Power Value
Ben Graham Fair Value
FAQ
What is Royalty Pharma plc Reverse DCF (discounted cash flow) valuation?
As of Dec 31, 2024, Royalty Pharma plc's Reverse Discounted Cash Flow (DCF) valuation estimates its Free Cash Flow growth at (28.7%).
What is Royalty Pharma plc WACC?
As of Dec 31, 2024, Royalty Pharma plc's Weighted Average Cost of Capital (WACC) is approximately 5.0%.
What is Royalty Pharma plc Free Cash Flow?
As of Dec 31, 2024, Royalty Pharma plc's Free Cash Flow is $2,769.5M.